Abstract:Disturbance of innate and adaptive immune systems is responsible for β-cell destruction in type 1 diabetes (T1D). Although increasing evidence indicated a crucial role for B cells in disease pathogenesis, exactly how B-cell subsets contribute to T1D remains unclear. This study aimed to evaluate the potential role of B-cell subset in the development of T1D. We enrolled 56 people with T1D, including 8 people receiving mesenchymal stromal cell (MSC) treatment, 22 people with T2D, and 26 healthy controls. ELISPOT assay was used to assess the role of B-cell subset in activation of diabetogenic T cells. NOD mice and adoptive transfer assays were utilized to study the role of B-cell subset in T1D in vivo. Plasmablasts, but not naïve, unswitched or switched memory B cells, were increased in patients with recent-onset T1D, compared with those with long-term T1D, T2D and healthy controls. In patients with recent-onset T1D, plasmablast number negatively correlated with fasting C-peptide and area under the curve of C-peptide. Plasmablasts decreased in line with an improvement of residual β-cell function 3 months after MSC treatment. Compared with other B-cell subsets, plasmablasts expressed a high level of CD86, which negatively correlated with the residual β-cell function while positively correlated with the number of islet autoantibodies. ELISPOT assay further showed that plasmablasts isolated from participants with T1D induced a dramatic increase of interferon-γ secretion in GAD65 stimulated T cells. Compared with euglycemic NOD mice, the number of plasmablasts was increased in the spleen, pancreatic lymph nodes, and islets of diabetic NOD mice. Moreover, adoptive transfer of plasmablasts mixed with T cells from diabetic NOD mice into NOD/SCID mice accelerated the development of T1D. These data firstly demonstrated that plasmablasts play a vital role in immune disturbance, further expanding the knowledge of T1D pathogenesis. Plasmablasts may serve as a novel therapeutic target in T1D. Disclosure B. Yan: None. Q. Ling: None. J. Lu: None. D. Zhu: None.

Type 1 diabetes depends on CD4-driven expression of the transcriptional repressor, Bcl6

A Public BCR Present in a Unique Dual-Receptor-Expressing Lymphocyte from Type 1 Diabetes Patients Encodes a Potent T Cell Autoantigen

B lymphocyte "original sin" in the bone marrow enhances islet autoreactivity in type 1 diabetes-prone nonobese diabetic mice

Altered B Cell Metabolic Pathways Characterize Type 1 Diabetes Progression

Essential Roles Of Tgf-Beta In Anti-Cd3 Antibody Therapy: Reversal Of Diabetes In Nonobese Diabetic Mice Independent Of Foxp3(+) Cd4(+) Regulatory T Cells

Increased plasmablasts enhance T cell-mediated beta cell destruction and promote the development of type 1 diabetes

1673-P: Plasmablasts Contribute to the Development of Type 1 Diabetes Via Enhancing T-Cell Cytotoxicity

Insulin-Reactive T Cells Convert Diabetogenic Insulin-Reactive VH125 B Cells Into Tolerogenic Cells by Reducing Germinal Center T:B Cell Interactions in NOD Mice

The CD318/CD6 axis limits type 1 diabetes islet autoantigen-specific human T cell activation

Toll-like Receptor 4 on Islet Β Cells Senses Expression Changes in High-Mobility Group Box 1 and Contributes to the Initiation of Type 1 Diabetes

Innate immune stimulation of whole blood reveals IFN-1 hyper-responsiveness in type 1 diabetes

Transcriptional Control of Pancreatic Β-Cell Identity and Plasticity During the Pathogenesis of Type 2 Diabetes.

Innate Immunity in Type 1 Diabetes

Unexpected acceleration of type 1 diabetes by transgenic expression of B7-H1 in NOD mouse peri-islet glia

B lymphocyte alterations accompany abatacept resistance in new-onset type 1 diabetes

Type 1 Diabetes: A Chronic Anti-Self-Inflammatory Response

Expansion of Th17 Cells and Functional Defects in T Regulatory Cells Are Key Features of the Pancreatic Lymph Nodes in Patients With Type 1 Diabetes

Reactivated CD4+Tm Cells of T1D Patients and Siblings Display an Exaggerated Effector Phenotype With Heightened Sensitivity to Activation-Induced Cell Death

B cell depletion in autoimmune diabetes: insights from murine models

Type 1 Diabetes: Etiology, Immunology, and Therapeutic Strategies

An imbalance of naive and effector T-cell phenotypes in early type 1 diabetes across conventional and regulatory subsets